GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
Completed · Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. Giving GM-CSF and thalidomide before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well giving GM-CSF together with thalidomide works in treating patients undergoing surgery for high-risk prostate cancer.
Key facts
- Study ID
- NCT00400517
- Run by
- The Cleveland Clinic
- People needed
- 28
- Starts
- 2003-03-01
- Expected to finish
- 2008-06-01
- Last updated by the study team
- 2018-08-28
Who can join
Age: any, up to 120. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Cleveland Clinic — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.